[go: up one dir, main page]

NO944803L - Farmasöytisk preparat for kontrollert frigivelse - Google Patents

Farmasöytisk preparat for kontrollert frigivelse

Info

Publication number
NO944803L
NO944803L NO944803A NO944803A NO944803L NO 944803 L NO944803 L NO 944803L NO 944803 A NO944803 A NO 944803A NO 944803 A NO944803 A NO 944803A NO 944803 L NO944803 L NO 944803L
Authority
NO
Norway
Prior art keywords
controlled release
pharmaceutical preparation
release pharmaceutical
solubility
water
Prior art date
Application number
NO944803A
Other languages
English (en)
Other versions
NO944803D0 (no
Inventor
Martin Howard Infeld
A Waseem Malick
Navnit Hargovindas Shah
Wantanee Phuapradit
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO944803D0 publication Critical patent/NO944803D0/no
Publication of NO944803L publication Critical patent/NO944803L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En nedbrytbar farmasøytisk sammensetning som gir en enestående kontrollert frigivelsesprofil av nullte orden inneholder en terapeutisk aktiv substans med en vannoppløselighet som ikke er større enn 80 mg/ml i vann ved 25'C, et hydroksypropylmetylcellu- losederivat og erosjonsmodifiserende midler avhengig av medikamentets oppløselighet og dets konsen- trasjon, slik som laktose og polyoksyalkylenderiva- ter av propylenglykol, samt andre inerte materialer, slik som bindemidler og smøremidler.
NO944803A 1993-12-13 1994-12-12 Farmasöytisk preparat for kontrollert frigivelse NO944803L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/166,123 US5393765A (en) 1993-12-13 1993-12-13 Pharmaceutical compositions with constant erosion volume for zero order controlled release

Publications (2)

Publication Number Publication Date
NO944803D0 NO944803D0 (no) 1994-12-12
NO944803L true NO944803L (no) 1995-06-14

Family

ID=22601916

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944803A NO944803L (no) 1993-12-13 1994-12-12 Farmasöytisk preparat for kontrollert frigivelse

Country Status (22)

Country Link
US (1) US5393765A (no)
EP (1) EP0662322B1 (no)
JP (1) JP2966745B2 (no)
KR (1) KR950016783A (no)
CN (1) CN1110135A (no)
AT (1) ATE214919T1 (no)
AU (1) AU688807B2 (no)
BR (1) BR9404953A (no)
CA (1) CA2136118A1 (no)
CO (1) CO4340618A1 (no)
CZ (1) CZ287718B6 (no)
DE (1) DE69430237T2 (no)
ES (1) ES2171431T3 (no)
HU (1) HU219227B (no)
IL (1) IL111920A (no)
NO (1) NO944803L (no)
NZ (1) NZ270058A (no)
PL (1) PL306245A1 (no)
RU (1) RU2174832C2 (no)
TW (1) TW438597B (no)
UA (1) UA41887C2 (no)
ZA (1) ZA949711B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5869079A (en) † 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6551616B1 (en) 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6337091B1 (en) 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6503528B1 (en) * 1999-11-19 2003-01-07 Abbott Laboratories Polymeric compositions and a method of making the same
WO2003024427A1 (en) 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
JP2005526079A (ja) * 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
US20040043073A1 (en) * 2002-06-14 2004-03-04 Chih-Ming Chen Pharmaceutical compositions for drugs having pH-dependent solubility
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
MXPA05008033A (es) * 2003-01-28 2006-04-28 Collegium Pharmaceutical Inc Composiciones de milnacipran en forma de multiparticulas para administracion oral.
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
WO2004112711A2 (en) * 2003-06-16 2004-12-29 Andrx Pharmaceuticals, Llc Oral extended-release composition
AU2004258953B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004258949B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2007502296A (ja) * 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション ロバストペレット
EP1653924A4 (en) * 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In ANTIBIOTICS, USE AND FORMULATION ASSOCIATED
CA2535780A1 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
CA2538064C (en) * 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1701705A4 (en) * 2003-12-24 2007-08-08 Advancis Pharmaceutical Corp IMPROVED ABSORPTION OF DOSAGE FORMS WITH MODIFIED RELEASE
JP2008505124A (ja) * 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
US20060024368A1 (en) * 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
WO2006031024A1 (en) * 2004-09-15 2006-03-23 Gl Pharmtech Corp. A sustained-release tablet containing doxazosin mesylate
KR100920856B1 (ko) * 2004-11-30 2009-10-09 (주)아모레퍼시픽 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
JP2011500724A (ja) * 2007-10-19 2011-01-06 パーデュ リサーチ ファンデーション 結晶性化合物の固体製剤
SG171444A1 (en) 2009-01-23 2011-07-28 Acraf Controlled release pharmaceutical or food formulation and process for its preparation
CN116987014A (zh) * 2016-11-09 2023-11-03 诺沃梅迪科斯有限公司 1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
US9980946B1 (en) 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation
KR20210079216A (ko) * 2019-12-19 2021-06-29 (주)셀트리온 시벤졸린 또는 이의 염을 포함하는 약학 제형

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4556678A (en) * 1982-06-24 1985-12-03 Key Pharmaceuticals, Inc. Sustained release propranolol tablet
IL70071A (en) * 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
FR2535202B1 (fr) * 1982-11-03 1985-08-09 Fabre Sa Pierre Comprimes de theophylline a liberation controlee et leur procede de fabrication
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
FR2591105B1 (fr) * 1985-12-11 1989-03-24 Moet Hennessy Rech Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5284662A (en) * 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
SE9003904D0 (sv) * 1990-12-07 1990-12-07 Astra Ab Method for the manufacture of a pharmaceutical dosage form
EP0664118B1 (en) * 1991-10-04 1999-08-25 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release tablet
DE69301742T2 (de) * 1992-02-17 1996-08-14 Siegfried Ag Pharma Darreichungsformen mit verlaengerter Wirkstoffreigabe

Also Published As

Publication number Publication date
AU8023294A (en) 1995-06-22
UA41887C2 (uk) 2001-10-15
DE69430237D1 (de) 2002-05-02
CO4340618A1 (es) 1996-07-30
ZA949711B (en) 1995-08-21
RU94043809A (ru) 1996-11-10
HUT75456A (en) 1997-05-28
DE69430237T2 (de) 2002-07-18
EP0662322A3 (en) 1997-01-29
ATE214919T1 (de) 2002-04-15
EP0662322B1 (en) 2002-03-27
EP0662322A2 (en) 1995-07-12
PL306245A1 (en) 1995-06-26
US5393765A (en) 1995-02-28
AU688807B2 (en) 1998-03-19
BR9404953A (pt) 1995-08-08
CA2136118A1 (en) 1995-06-14
JP2966745B2 (ja) 1999-10-25
RU2174832C2 (ru) 2001-10-20
NZ270058A (en) 1996-07-26
CN1110135A (zh) 1995-10-18
IL111920A0 (en) 1995-03-15
KR950016783A (ko) 1995-07-20
HU9403496D0 (en) 1995-02-28
ES2171431T3 (es) 2002-09-16
IL111920A (en) 1999-08-17
CZ287718B6 (en) 2001-01-17
TW438597B (en) 2001-06-07
CZ312794A3 (en) 1995-09-13
NO944803D0 (no) 1994-12-12
HU219227B (en) 2001-03-28
JPH07196535A (ja) 1995-08-01

Similar Documents

Publication Publication Date Title
NO944803L (no) Farmasöytisk preparat for kontrollert frigivelse
ATE284861T1 (de) N-aralkylaminotetraline als neuropeptid-y-y5- rezeptorliganden
TNSN98090A1 (fr) Formulations pharmaceutiques contenant du voriconazole, et procede pour leur preparation.
SE9401728D0 (sv) New compounds II
WO2003028715A3 (en) Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
LV10268A (lv) Terapeitiski aktivs benzimidazols un ta iegusanas panemiens
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
EA200702648A1 (ru) Фармацевтическая композиция, пригодная для введения один раз в день
AR015894A1 (es) Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona e insulina para la preparacion de un medicamento y composicion farmaceuticaque contiene dichos compuestos
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
AR023563A1 (es) Monohidrato de hidrocloruro de un derivado de tiazolidin-2,4-diona, una composicion farmaceutica y el uso del mismo para la fabricacion de un medicamento
GEP20043377B (en) Pharmaceutical Complex
WO2001016111A3 (en) Hypoglycemic sulfonyl pyrazolones and pyrazolines
EP1051993A3 (en) 5HT1 receptor agonists and either a COX-2 inhibitor or NSAID for the treatment of migraine
EP1051995A3 (en) 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine
EP1064967A3 (en) 5HT1 receptor agonists, caffeine and either a COX-2 inhibitor or NSAID for the treatment of migraine
HRP20010344B1 (en) Novel method of treatment
EP1051994A3 (en) 5HT1 receptor agonists and a COX-2 inhibitor for the treatment of migraine
CY1107421T1 (el) Τρυγικα αλατα παραγωγου θειαζολιδινοδιονης
ECSP034528A (es) Sales de sodio de 5-(4-(n-methyl-n-(2-piridil)amino)etoxi)bencil)tiazolidino-2,4-diona
DE69905490D1 (de) Benzofuranderivate, verfahren zu ihrer herstellung, ihre anwendung als medikament und sie enthaltende pharmazeutische zubereitungen
WO1997049431A3 (en) Use of oligosaccharides for neutralising e. coli toxins
CO4340557A1 (es) Formulaciones farmaceuticas que comprenden derivados del acido clavulanico y su uso
ECSP003435A (es) Nuevos compuestos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application